HER2-positives Mamma-Ca: Perjeta in der adjuvanten Therapie signifikant überlegen
Crossref DOI link: https://doi.org/10.1007/s15013-017-1157-4
Published Online: 2017-04-08
Published Print: 2017-04
Update policy: https://doi.org/10.1007/springer_crossmark_policy
red,
